IMPACT THERAP-B (07630.HK): Executive director and CEO increases stake with purchase of 100,000 shares, holding rises to approximately 6.564%

NewTimeSpace News: On 3 September 2026, IMPACT Therapeutics, Inc. (stock code: 07630) announced that Dr. Cai Suixiong, executive director and chief executive officer of the Company, has recently purchased an aggregate of 100,000 ordinary shares of the Company on the open market at an average price of approximately HKD 14.6105 per share, representing approximately 0.035% of the total number of issued shares of the Company.

Immediately after the purchase, Dr. Cai has interests in an aggregate of 18,540,884 shares, representing approximately 6.564% of the total issued share capital of the Company as of the date of this announcement. Dr. Cai expressed confidence in the overall development prospects and potential growth of the Group, and, subject to compliance with applicable laws and regulatory requirements, does not rule out further increases in his shareholding in the Company at appropriate times.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.